
# **TECHNICAL NOTE**

QUALITY AND REGULATORY
CONSIDERATIONS FOR THE USE OF
VITAMIN A SUPPLEMENTS IN PUBLIC
HEALTH PROGRAMMES FOR INFANTS AND
CHILDREN AGED 6-59 MONTHS







## **TECHNICAL NOTE**

# QUALITY AND REGULATORY CONSIDERATIONS FOR THE USE OF VITAMIN A SUPPLEMENTS IN PUBLIC HEALTH PROGRAMMES FOR INFANTS AND CHILDREN AGED 6-59 MONTHS



Technical note: quality and regulatory considerations for the use of vitamin A supplements in public health programmes for infants and children aged 6–59 months

ISBN 978-92-4-151630-3

#### © World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <a href="https://creativecommons.org/licenses/by-nc-sa/3.0/igo">https://creativecommons.org/licenses/by-nc-sa/3.0/igo</a>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation**. Technical note: quality and regulatory considerations for the use of vitamin A supplements in public health programmes for infants and children aged 6–59 months. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <a href="http://apps.who.int/iris">http://apps.who.int/iris</a>.

Sales, rights and licensing. To purchase WHO publications, see <a href="http://apps.who.int/bookorders">http://apps.who.int/bookorders</a>. To submit requests for commercial use and queries on rights and licensing, see <a href="http://www.who.int/about/licensing">http://www.who.int/about/licensing</a>.

**Third-party materials**. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Switzerland

Cover design and layout: Alberto March (Barcelona, Spain)

## **CONTENTS**

ABBREVIATIONS	IV
ACKNOWLEDGEMENTS	V
Financial support	V
SCOPE AND PURPOSE	1
VITAMIN A	1
Functions and dietary sources	1
Public health relevance	2
VITAMIN A SUPPLEMENTATION	2
From a few deficiency surveys to a global programme	2
Efficacy of vitamin A supplements in infants and children aged 6–59 months	3
Safety evidence	5
WHO guidelines and recommendations on vitamin A supplementation in infants and children aged $6-59$ months	7
QUALITY-RELATED REGULATORY STANDARDS FOR VITAMIN A AS A MEDICAL PRODUCT	9
WHO medicines quality assurance guidelines	10
Vitamin A finished product specifications	15
CLOSING REMARKS ANS KNOWLEDGE GAPS	22
REFERENCES	23
ANNEX 1 THE INTERNATIONAL PHARMACOPOEIA RETINOL ORAL SOLUTION MONOGRAPH	30
ANNEX 2 UNITED STATES PHARMACOPEIA VITAMIN A ORAL LIQUID PREPARATION MONOGRAPH	32
ANNEX 3 NUTRITION INTERNATIONAL/UNITED NATIONS CHILDREN'S FUND PRODUCT TECHNICAL SPECIFICATIONS	34

### **ABBREVIATIONS**

**CI** confidence interval

**DEVTA trial** Deworming and Enhanced Vitamin A trial

**DTP** diphtheria, tetanus and pertussis

**FAO** Food and Agriculture Organization of the United Nations

**GMP** good manufacturing practices

**ICSR** individual case safety report

**IU** international unit

**IVACG** International Vitamin A Consultative Group

MCV measles-containing vaccine

**RE** retinol equivalent

**RR** relative risk

**UNICEF** United Nations Children's Fund

**WHO** World Health Organization

#### **ACKNOWLEDGEMENTS**

This technical note was coordinated by the World Health Organization (WHO) Department of Nutrition and Food Safety. Mr Filiberto Beltran-Velazquez, with technical support from Dr Maria Nieves Garcia-Casal, Dr Juan Pablo Peña-Rosas and Dr Lisa Rogers, oversaw the preparation of this document. WHO gratefully acknowledges the technical input of Andrea Monahan and Leeza Sharma from Nutrition International, as well as technical staff from UNICEF Supply Division.

The special thanks are extended to (in alphabetical order): Camille Elyse Jones, Bryan Gannon, Saurabh Mehta and Pratiwi Ridwan, for the literature review used to inform the section on the efficacy and safety of vitamin A supplements.

We appreciate the feedback provided by (in alphabetical order): Samvel Azatyan, Ahmed Bellah, Francesco Branca, Jan Debyser, Luz Maria De-Regil, Angela De Silva, Alison Fleet, Valeria Gigante, Tracey S Goodman, Alison Greig, Noha lessa, Abraham Kahsay, Sabine Kopp, Erin McLean, Laura Nic Lochlainn, Henrik Nielsen, Adelheid Onyango, Lisa Rogers, Herbert Schmidt and Juliawati Untoro.

Thanks are also due to Hala Boukerdenna from the WHO Eastern Mediterranean Region for preparing a first draft of this document. Rosa A Seminario from the WHO Department of Nutrition and Food Safety, provided logistic support.

#### **Financial support**

WHO gratefully acknowledges the financial contribution of Nutrition International (Canada) and the Bill & Melinda Gates Foundation (United States of America) for this work.



https://www.yunbaogao.cn/report/index/report?reportId=5\_24907

